ERBB2 and breast carcinoma: For the rest of the evaluated cell lines, a possible resistant mechanism is active as described in human breast cancer, like the overexpression of TLR4 (toll-like receptor-4), overexpression of RNF8 (finger protein 8), and overexpression of HER2, among others [106,107].